Warning! GuruFocus detected
2 Severe warning signs
with 8AT.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Aclaris Therapeutics Inc
NAICS : 541714
SIC : 8731
ISIN : US00461U1051
Description
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.71 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -5.52 | |||||
| Beneish M-Score | -1.9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 26.7 | |||||
| 3-Year EBITDA Growth Rate | 16.2 | |||||
| 3-Year EPS without NRI Growth Rate | 22.1 | |||||
| 3-Year FCF Growth Rate | 7.8 | |||||
| 3-Year Book Growth Rate | -23.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -20.26 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 45.03 | |||||
| 9-Day RSI | 38.31 | |||||
| 14-Day RSI | 34.74 | |||||
| 3-1 Month Momentum % | -29.99 | |||||
| 6-1 Month Momentum % | 89.08 | |||||
| 12-1 Month Momentum % | 73.21 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.99 | |||||
| Quick Ratio | 3.99 | |||||
| Cash Ratio | 6.45 | |||||
| Days Sales Outstanding | 6.46 | |||||
| Days Payable | 185.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -20.8 | |||||
| Shareholder Yield % | -43.57 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 17.43 | |||||
| Operating Margin % | -280.57 | |||||
| Net Margin % | -705.44 | |||||
| FCF Margin % | -306.6 | |||||
| ROE % | -91.88 | |||||
| ROA % | -70.6 | |||||
| ROIC % | -78.31 | |||||
| 3-Year ROIIC % | 22.8 | |||||
| ROC (Joel Greenblatt) % | -3988.31 | |||||
| ROCE % | -32.1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 6.88 | |||||
| PB Ratio | 1.1 | |||||
| Price-to-Tangible-Book | 1.1 | |||||
| EV-to-EBIT | -1.01 | |||||
| EV-to-EBITDA | -1.03 | |||||
| EV-to-Revenue | 2.85 | |||||
| EV-to-Forward-Revenue | 4.1 | |||||
| EV-to-FCF | -0.95 | |||||
| Price-to-GF-Value | 0.34 | |||||
| Price-to-Net-Current-Asset-Value | 2.77 | |||||
| Price-to-Net-Cash | 1.23 | |||||
| Earnings Yield (Greenblatt) % | -99.01 | |||||
| FCF Yield % | -32.57 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aclaris Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 17.489 | ||
| EPS (TTM) (€) | -1.424 | ||
| Beta | -0.1 | ||
| 3-Year Sharpe Ratio | -0.04 | ||
| 3-Year Sortino Ratio | -0.06 | ||
| Volatility % | 139.42 | ||
| 14-Day RSI | 34.74 | ||
| 14-Day ATR (€) | 0.056025 | ||
| 20-Day SMA (€) | 1.569975 | ||
| 12-1 Month Momentum % | 73.21 | ||
| 52-Week Range (€) | 0.8996 - 4.52 | ||
| Shares Outstanding (Mil) | 108.15 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aclaris Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aclaris Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Aclaris Therapeutics Inc Frequently Asked Questions
What is Aclaris Therapeutics Inc(FRA:8AT)'s stock price today?
The current price of FRA:8AT is €1.47. The 52 week high of FRA:8AT is €4.52 and 52 week low is €0.90.
When is next earnings date of Aclaris Therapeutics Inc(FRA:8AT)?
The next earnings date of Aclaris Therapeutics Inc(FRA:8AT) is 2025-05-07 Est..
Does Aclaris Therapeutics Inc(FRA:8AT) pay dividends? If so, how much?
Aclaris Therapeutics Inc(FRA:8AT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers